Zelira Therapeutics Limited (ASX:ZLD)


right-arrow Created with Sketch. -0.001 (-3.33%)
MCAP $38.43M
Last trade 15.28pm 25/01/2022 20mins delayed

Latest Announcements

20/01/2022ZLDZelira Therapeutics Limited
18/01/2022ZLDZelira Therapeutics Limited
13/01/2022ZLDZelira Therapeutics Limited
13/01/2022ZLDZelira Therapeutics Limited
12/01/2022 Price SensitivePSZLDZelira Therapeutics Limited
10/01/2022 Price SensitivePSZLDZelira Therapeutics Limited
23/12/2021ZLDZelira Therapeutics Limited
16/12/2021 Price SensitivePSZLDZelira Therapeutics Limited

Company Overview

Zelira Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. The Company's lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. It is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care product containing cannabinoids and based on the patented technology of blackseed oil and zinc.

ZLD in the news

Zelira Therapeutics (ZLD) has received a $1.29 million cash refund under the…
Zelira Therapeutics (ZLD) expands into the New Zealand cannabinoid-based medicines market via…
Zelira Therapeutics (ZLD) receives ethics approval for its Phase 2a clinical trial…
Zelira Therapeutics (ZLD) signs a licensing deal for its Enhanced Distillate Capture…

Search Previous Announcements